Berchtold P
Medizinische Universitätsklinik, Inselspital Bern.
Schweiz Med Wochenschr. 1990 Jun 9;120(23):866-9.
The short-term benefit of high-dose intravenous gammaglobulin (IvIgG) in autoimmune diseases is widely accepted in patients with chronic immune thrombocytopenic purpura (ITP). Recent studies reported remission or stabilization of the disease in some patients receiving long-term IvIgG therapy. It has been suggested that this long-term effect may be due to antiidiotypic antibodies in IvIgG down-regulating the immune response in chronic ITP. Because of the high costs and the transient effect in most instances, this treatment should not be used routinely. IvIgG may be considered in severely thrombocytopenic patients with chronic ITP who develop serious bleeding.
大剂量静脉注射丙种球蛋白（IvIgG）对自身免疫性疾病的短期益处已被慢性免疫性血小板减少性紫癜（ITP）患者广泛接受。最近的研究报告称，一些接受长期IvIgG治疗的患者病情缓解或稳定。有人提出，这种长期效果可能是由于IvIgG中的抗独特型抗体下调了慢性ITP中的免疫反应。由于成本高昂且在大多数情况下效果短暂，这种治疗不应常规使用。对于患有慢性ITP且出现严重出血的重度血小板减少患者，可考虑使用IvIgG。
